Is olaparib the only PARP inhibitor that has been approved?
- 1 people answered
Edit Tags
Tags are used to find the best answers
You might also be interested in
There’s little that scares women more than finding a breast lump, especially if you know you’re at risk for breast cancer because of family history or for other reasons. But if it happens to you, the first thing to do is take a deep breath and try to stay calm, because that lump doesn’t necessarily ....
You can get in touch with the following associations for financial help. Cancer Patients Aid Association King George V. Memorial, Smt. Panadevi Dalmia Cancer, Management Centre, Dr. E. Moses Road, Mahalaxmi, Mumbai 400 011, Maharashtra, India. Telephone: +91 22 24924000 or +91 22 24928775 ....
Breast cancer can be diagnosed at different stages and can grow at different rates. This means people can have different treatments, depending on what will work best for them. To determine if your symptoms are caused by breast cancer or a benign breast condition, your doctor will do a thorough ph....
Credihealth is not a medical practitioner and does not provide medical advice. You should consult your doctor or with a healthcare professional before starting any diet, exercise, supplementation or medication program. Know More
লেখা:Dr. Nitika Sharma - BDS
পর্যালোচনা করা হয়েছে:Dr. Rakesh Kumar - MBBS, MS
Rahul Sharma
Yes, PARP inhibitors are relatively newer class of drugs and scientists have just begun to explore their functionality and usage in Cancer treatment. LYNPARZA is the first and only PARP inhibitor approved in 2 distinct settings: For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. For the treatment of adult patients with suspected deleterious germline BRCA-mutated advanced ovarian cancer which has been treated with 3 or more prior lines of chemotherapy. Patients should be selected for therapy based on an FDA-approved companion diagnostic for LYNPARZA. Poly (ADP-ribose) Polymerase, or PARP, enzymes mediate DNA repair by transferring ADP-ribose units to preexisting ADP-ribose chains on proteins and to proteins. This ADP–ribosylation process recruits DNA repair enzymes, thereby maintaining genomic integrity. Inhibiting this process can lead to the accumulation of DNA damage and, ultimately, cell death.